Ad hoc announcement pursuant to Art. 53 LR Mid-term sales guidance rolled forward to +5-6% cc CAGR for 2025-2030, following upgrade of 2024-2029 guidance to +6% cc1Peak sales guidance upgraded for Kisqali and Scemblix; Novartis now has eight de-risked, in-market assets with USD 3-10 billion peak sales potential15+ potentially submission-enabling readouts expected in the next two years to fuel long-term growth Pipeline includes 30+ potential high-value medicines, with 10+ licensed or acquired in the past two ...